Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Paclitaxel Protein-bound Particles vs Abraxane in Breast Cancer
NCT07096869Phase 1Recruiting
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of paclitaxel albumin-bound in breast cancer (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Peak Plasma Concentration at 72 hours, Area under the plasma concentration versus time curve AUC0-t at 72 hours and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
paclitaxel albumin-bound
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07096869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07096869.